Anlotinib Completed Phase 2 / 3 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01924195Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0302)